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Abstract
We aim to define a site-specific robustness protocol to be used during the 
clinical plan evaluation process. Plan robustness of 16 skull base IMPT plans 
to systematic range and random set-up errors have been retrospectively and 
systematically analysed. This was determined by calculating the error-bar 
dose distribution (ebDD) for all the plans and by defining some metrics used 
to define protocols aiding the plan assessment. Additionally, an example 
of how to clinically use the defined robustness database is given whereby 
a plan with sub-optimal brainstem robustness was identified. The advantage 
of using different beam arrangements to improve the plan robustness was 
analysed. Using the ebDD it was found range errors had a smaller effect on 
dose distribution than the corresponding set-up error in a single fraction, and 
that organs at risk were most robust to the range errors, whereas the target was 
more robust to set-up errors. A database was created to aid planners in terms 
of plan robustness aims in these volumes. This resulted in the definition of 
site-specific robustness protocols. The use of robustness constraints allowed 
for the identification of a specific patient that may have benefited from a 
treatment of greater individuality. A new beam arrangement showed to be 
preferential when balancing conformality and robustness for this case. The 
ebDD and error-bar volume histogram proved effective in analysing plan 
robustness. The process of retrospective analysis could be used to establish 
site-specific robustness planning protocols in proton therapy. These protocols 
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allow the planner to determine plans that, although delivering a dosimetrically 
adequate dose distribution, have resulted in sub-optimal robustness to these 
uncertainties. For these cases the use of different beam start conditions may 
improve the plan robustness to set-up and range uncertainties.
Keywords: radiotherapy, robustness, cancer, proton beam therapy, treatment 
planning
(Some figures may appear in colour only in the online journal)
1. Introduction
Protons have a finite range, highly dependent on the electron density of the material they 
are traversing, resulting in a steep dose gradient at the distal edge of the Bragg peak. Due to 
these characteristics and the advancements in computation and technology it has led to the 
ability to produce and deliver treatments with greater conformality; sparing normal tissue 
through the use of intensity modulation, multiple fields and steep dose gradients. For these 
reasons proton therapy is considered to be advantageous in treating most childhood cancers 
and certain adult cancers; including those of the skull base and head and neck (Jones 2008, 
Ares et al 2009, Durante and Loeffler 2010, Allen et al 2012, De Ruysscher et al 2012). 
Besides meeting planning constraints the plan is also required to meet the aims of the planner 
at each and every fraction, therefore ensuring it is robust to uncertainties such as Hounsfield 
Unit (HU) error or patient motion. Due to the steep dose gradients and range sensitivity of 
proton therapy, robustness is a real concern (Lomax 2008b, Lassen-Ramshad et al 2011). 
Several factors will influence a plan’s robustness including the delivery method, immobili-
zation technique and beam orientation. Therefore, balancing the compromise between plan 
conformality and plan robustness through careful positioning of dose gradients is critical 
to successful planning and optimum treatment delivery (Lomax 2004, Albertini et al 2011, 
McGowan et al 2013).
At the fore-front of proton beam therapy is three-dimensional intensity modulated par-
ticle therapy (3D IMPT), the equivalent to intensity modulated radiation therapy in con-
ventional x-ray radiotherapy, whereby Bragg peaks are optimally weighted and placed as 
‘spots’ throughout the target volume (Lomax 1999). The spot weight is essentially its flu-
ence (the number of protons in a given spot). Due to the number of spots required to fill 
the target an optimization algorithm is required to determine the optimal solution for their 
individual weights. Due to the highly degenerate nature of intensity modulation optimiza-
tion (Webb 2003, Albertini et al 2011), there exist many solutions to the given problem of 
delivering a homogenous dose to target whilst ensuring the dose to certain organs at risk 
(OARs) are within predefined constraints. Despite there being many solutions that may sat-
isfy the dosimetric constraints, some of these solutions may offer greater plan robustness and 
therefore a greater chance of cure whilst limiting the chance of normal tissue complications. 
Several authors have investigated this through including robustness in the optimization itself 
(Unkelbach et al 2007, Pflugfelder 2008, Chen 2012) or by altering the start conditions, such 
as number of beams and their orientation to obtain solutions, to satisfy both dosimetric and 
robustness requirements (Lomax 2008a, Albertini et al 2010).
Ultimately, the trade-off between plan conformality and plan robustness needs to be 
explored more thoroughly as well as the establishment of site-specific robustness thresholds. 
Increasing plan robustness may lead to a decrease in plan conformality. Nevertheless, clinical 
experience so far has been achieved without considering the robustness of the plan. Although 
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the importance of including robustness during the plan analysis is recognized, it is not yet 
clear how much the nominal dose distribution can be compromised without compromising the 
patient’s treatment. The actual status is therefore that the robustness analysis is not yet fully 
included into the clinical plan evaluation phase. On one hand, no commercial planning system 
has a robustness evaluation module integrated. On the other hand, to the best of our knowl-
edge, the research centres that have developed their own robustness analysis tool, are not yet 
being clinically using to make decisions for all treated patients. It is therefore of paramount 
importance to find a way to introduce the robustness analysis into the clinical plan evaluation 
process, without compromising the nominal dosimetric plan quality.
In this paper we suggest a way to introduce the robustness analysis gradually into the clinic 
process of plan evaluation. In particular we suggest a way to define site-specific, and also 
centre-specific, robustness database by retrospectively analysing patients already treated in 
the specific centre. This database can be used during the plan evaluation and during the plan 
calculation phase to aid the planner to select the optimal plan.
2. Methods and materials
We propose to define site-specific robustness protocols by retrospectively analysing the 
robustness, to both range and set-up errors, for a sample of Chordoma and Chondrosarcoma 
plans. All plans were clinically acceptable and had been delivered in the last 5 years at the 
Paul Scherrer Institute (PSI). All plans were calculated using the in-house treatment planning 
system at PSI. The treatment planning system uses a pencil beam model to calculate absolute 
dose delivered to the patient (Scheib and Pedroni 1992, Pedroni et al 2005) and uses a quasi-
Newton optimization technique (Lomax 1999). The model parameters have been adjusted 
to fit the measured data, which takes into account range straggling, proton energy loss and 
the width of the initial energy spectrum. To take into account density heterogeneities in the 
patient, computed tomography (CT) data is converted into water equivalent depth using a ray-
casting model (Schaffner et al 1999).
To determine plan robustness the set-up and range uncertainties were modelled using the 
method proposed by Albertini et al (2011) and later validated by Casiraghi et al (2013). This 
method will be briefly described here.
2.1. Set-up uncertainty
The effect of random set-up uncertainty on plan robustness was simulated by recalculating 
the nominal dose distribution on 14 isocentrically shifted CT data sets (Albertini et al 2011). 
The shifts used were applied along the major anatomical axes and their indices in both posi-
tive and negative directions (equivalent to the six faces and eight vertices of a cube) resulting 
in multiple spatially shifted does distributions associated with each shifted CT data set. Bolsi 
et al (2008) showed that the use of a remote patient positioning device reduced systematic set-
up errors to negligible values (below 0.6 mm), whereas random set-up errors of over 2 mm can 
be observed, depending on tumour location and immobilization device used. Using these data 
a 3D shift vector was calculated from the standard deviation of each shift in left-right (LR), 
anterior-posterior (AP) and cranium-caudal (CC) directions which represents of the radius of 
the spherical error-space used in this analysis. Following the same method as Albertini et al 
(2011) a shift of magnitude equivalent to a confidence interval of 85% was applied. In particu-
lar shifts of ±3.2 mm and ±4.7 mm were used for bite block and for head mask fixation devices 
respectively. The nominal dose distribution and each recalculated dose distribution are then 
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combined into one ‘error-bar’ dose distribution (ebDD) by storing in each voxel the difference 
between the maximum and minimum value for that corresponding voxel from all the plans. 
This amplitude of dose errors, ΔDi, in each voxel is calculated using formula (1).
Δ = −+ − − + − −( ) ( )D D D D D D D D D Max ,  ,...,  ,  Min ,  ,..., ,   ,i i i i i i i i i(random) LR LR CC nom LR LR CC nom (1)
The model then, assumes that the value in every voxel represents a dose-error-bar that 
brackets all the possible deviations from the nominal dose distribution that can be detected 
when patient shifts within an 85% confidence interval occur (Casiraghi et al 2013).
2.2. Range uncertainty
Radiotherapy plans are generally produced using a single CT data set of the patient and so 
any uncertainties in either the HUs, or their conversion to relative proton stopping power, will 
lead to a systematic uncertainty that will propagate throughout the treatment delivery (Lomax 
2008b). The effect of systematic range uncertainty on plan robustness was simulated by recal-
culating the nominal dose distribution on CT data with HUs altered by ±3%, thus to simulate 
an overshoot or an undershoot scenario (Lomax 2008b). In this case the ebDD is calculated 
using formula (2).
Δ =     −  + − + −( ) ( )D D D D D D DMax , , Min , , ,i i i i i i i(systematic) HU HU nom HU HU nom (2)
The robustness of each volume has been analysed by extracting the error-bar volume 
histogram (ebVH). The error-bar volume histograms represent a useful and simple tool to 
evaluate the quality of the treatment: the closer the histogram is to the ‘0-error’ line, the 
more robust the dose is to that specific error. In particular its similarity in presentation to 
the familiar dose volume histogram used conventionally in radiotherapy allows for easy 
integration into the planning process. Several metrics can be defined and analysed as for 
example the maximum error, the mean error and the volume receiving an error of 3, 5 and 
10% (Veb3, Veb5, Veb10%).
There is a greater clinical relevance in displaying the potential over-dosage error (highest 
minus nominal value) for the organ at risk and the under-dosage error (nominal minus lowest 
value) for the target volume, instead of the more general error-bar dose distribution (ebDD) 
discussed above. In this study we have distinguished between under-dosages and over-dosages 
when creating the database and advise the same for clinical use.
2.3. Retrospective robustness analysis
Chordomas and chondrosarcomas are treated to 74 Gy(RBE) and 68 Gy(RBE) respectively. 
Each treatment consists of three series delivering a given proportion of the total prescribed 
dose to the target at each fraction. The first series is generally comprised of a three-field 
uniform dose distribution (single field uniform dose (SFUD)) plan used to deliver up to 
34–40 Gy(RBE) of homogenous dose to the target volume. The only constraint within 
the SFUD plan optimization is to deliver a homogeneous dose to the target volume. As a 
consequence, the resulting target coverage will be robust to uncertainties, but at the com-
promise of OARs sparing (Albertini et al 2011). The following two series are comprised 
of 3D IMPT plans used to provide dose to the target whilst prioritizing OAR sparing. 
The second series then brings the dose to the primary target up to 54 Gy(RBE) sparing 
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some critical structures. The third series (bringing the dose up to 68 or 74 Gy(RBE)) is 
delivered to boost a reduced target volume with the IMPT plan aimed to spare the critical 
structures. In all these cases, the planning target volume was isotropically grown from the 
clinical target volume (CTV) by 5 mm. The dose constraints are mainly defined for the 
brainstem (64 Gy(RBE) on the surface, 53 Gy(RBE) in the centre) and 60 Gy(RBE) in the 
optical structures (Ares et al 2009). In the IMPT plans, all the fluences of all the fields are 
optimized simultaneously. Unlike SFUD treatments, IMPT can deliver a number of non-
uniform fields to produce the desired dose distribution.
The 3D-IMPT beam arrangement used clinically at PSI for the skull base is a four field, 
A(4f), beam arrangement illustrated in figure 1. This beam arrangement consists of four beams, 
two posterior obliques and two lateral obliques and was used to plan all IMPT plans in this study.
For each series, the plan robustness in the CTV for an underdose scenario was analysed 
for both types of uncertainty as well as the overdose scenario for the brainstem and for the 
optical structures. Due to their proximity with the target, the dose constraints defined for the 
brainstem and for the optical chiasm are driving the optimization outcome. The parameters 
measured include the mean and maximum dose uncertainties in the volume, the volume with 
an error of 3 and 5% (Veb3 and Veb5%), and where these uncertainties occur in relation to 
anatomy and field direction. From these data a table of robustness parameters was created to 
aid planners in the selection between robustness and conformality.
2.4. Example case
To illustrate how the robustness database could be clinically used in practice, we identified 
one plan as an outlier. This plan was found to be un-robust in the brainstem compared to the 
Figure 1. The A(4f) plan consists of four non-coplanar fields, two posterior obliques 
and two anterior lateral obliques. Clockwise from top left the beam angles used are 
(290°, 340°), (70°, 20°), (110°, 20°) and (250°, 340°), where the first angle is the gantry 
orientation and the second is the table orientation.
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sample. Due to the degeneracy associated with IMPT there exist many solutions to the given 
problem of ensuring target coverage whilst meeting dose and robustness constraints. Beyond 
changing the optimization itself (Unkelbach et al 2007, Pflugfelder 2008, Chen 2012), we can 
alter our starting conditions, such as number of beams and their orientation to obtain solutions 
to satisfy both dosimetric and robustness requirements. For this case, the plan was re-planned 
using four different beam arrangements.
Four additional start arrangements were investigated to determine which would be more 
optimal for this patient, including B(4f), B(6f), A(6f) and C(4f) shown in table 1 along with 
A(4f).
Each plan was created with the aim of keeping the dosimetric quality of the plan in the 
OARs and target as similar to those achieved in the A(4f) plan so that the degeneracy of 
robustness to start conditions could be investigated.
3. Results
3.1. Retrospective robustness analysis
Sixteen skull base 3D IMPT plans, series two and three, were retrospectively analysed in 
terms of robustness to systematic range and random set-up uncertainties. The volumes ana-
lysed were the brainstem, chiasm and the CTV. The results are shown in figure 2 where for 
each box plot the central mark is the median, the edges of the box are the 25th and 75th 
percentiles, the whiskers extend to the most extreme data points not considered outliers, and 
outliers are plotted individually. Outliers are considered to be points ±2.7σ. From the box plots 
in figure 2 it is seen that the impact of the random set-up error appears greater for an individual 
fraction than that resulting from the range error in all three volumes of interest (VOIs) for each 
parameter measured. Also that the mean and standard deviation in the range error was lower 
for the OARs than for the CTV; the opposite was true for the set-up error.
From our results an example of a robustness DATABASE for 3D IMPT skull-base plans 
has been generated (table 2). This table can be used to aid planners in visualizing the magni-
tude of effect that range and set-up errors can have on patient treatment in terms of percentage 
change from the nominal dose. The ranges represent the deviation from the nominal dose in 
that volume caused by the error for this patient sample. The values correspond to the 25th to 
75th percentiles as seen in the box plots in figure 2 for an over-dosage scenario to OAR and 
under-dosage scenario to the CTV. The lower limits are included to allow the planner to see 
where a compromise between conformality and robustness can be made.
Table 1. Descriptions of each plan.
Plan No. of fields Beam arrangement
A(4f) 4 Two posterior obliques and two anterior lateral 
obliques
B(4f) 4 Two lateral and two posterior lateral obliques
A(6f) 6 Two posterior oblique, two anterior lateral 
obliques and two lateral fields
B(6f) 6 Two posterior obliques, two anterior lateral 
obliques and two posterior lateral obliques
C(4f) 4 Two lateral fields and two oblique fields all 
coplanar
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Figure 2. Robustness results for 16 skull base IMPT plans from eight patients to both 
the range and set-up uncertainties modelled in (a) in the brainstem, (b) in the chiasm 
and (c) in the CTV. On each box plot the central mark is the median, the edges of 
the box are the 25th and 75th percentiles, the whiskers extend to the most extreme 
data points not considered outliers, and outliers are plotted individually. Outliers are 
considered points ±2.7σ.
Table 2. An example of a robustness DATABASE defined for IMPT plans for skull-
base cases.
VOI
Mean  
range (%)
Mean  
setup (%)
Veb3%  
range (%)
Veb5%  
range (%)
Veb5%  
setup (%)
Veb10%  
setup
Brainstem 1–2 6.5–9 2.5–17 5 63–85 15–37.5
Chiasm 1–1.5 8–15 <5 0 (Veb15%) (Veb17%)
<50 <4
CTV 1.5–2.5 5–8 17.5–28 2.5–11.5 32.5–72.5 3–25.8
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3.2. How to use the robustness database in practice: an example
To illustrate how the robustness database could be clinically used in practice, we will discuss 
here a clinical case. For patient X a nominal plan is generated and the robustness to set-up and 
range errors is calculated and compared to the robustness DATABASE table. If the robustness 
of plan X is within the defined values, the nominal plan is delivered. In contrast, if plan X 
has a robustness outside the DATABASE range for a given set of parameters for one or more 
volumes, the nominal plan has to be improved in terms of its robustness before delivering it 
to the patient. Or in the case where robustness is better than expected from the DATABASE it 
must be assured that plan conformality is not being compromised.
Of the plans retrospectively analysed, one plan showed to have a worse robustness in the 
brainstem compared to the sample. In particular, this plan resulted to have a potential mean 
range, Veb3% and Veb5% error in the brainstem of 3.9%, 43.5% and 15%, respectively, com-
pared to 1–2%, 2.5–17% and <5% in the DATABASE in table 2. The possibility of improving 
the plan robustness, without using robust optimization, but by changing the start conditions of 
the plan has been investigated. While ensuring plan quality is maintained, four dosimetrically 
equivalent plans were created by changing the field setup used. For each new plan, the robust-
ness and conformality of the CTV and each OAR considered during the optimization process, 
were analysed using the error bar dose histogram and by retrieving the robustness values for 
both the range and setup error from these (see tables 3 and 4).
The error bar dose histograms in the CTV for each plan created for this patient are shown in 
figure 3. The numbers in the plot key refer to the size of the area under each curve (the smaller 
the area, the greater the robustness). The B(4f) plan in figure 3(a) shows worse robustness in 
the CTV than the other plans. A comparison between the B(4f) and A(4f) nominal and ebDDs 
are shown in figure 3(c).
The B(4f) plan produces an underdose error to a larger volume of the target than the A(4f) 
plan. Table  3, shows that despite B(4f) having the worst plan robustness it only fails one 
robustness constraint, the mean range error which is 2.8% for the B(4f) plan compared to 
2.1% for the A(4f) plan. The constraint set in table 2 was 1.5–2.5%. Figure 3(b) shows the 
volume histograms from the set-up error, A(4f) is the most robust plan, though plan B(4f) is 
within the robustness constraints in table 3. The C(4f) plan shows to be the most robust plan 
to range errors, though it is the least robust plan to set-up errors.
Figure 4(a) shows the volume histograms of error bars from range errors in the brainstem 
from all plans. The A(4f) plan is least robust to range errors, as discussed in the previous sec-
tion of these results. Figure 4(d) shows the difference in ebDD between the B(4f) and A(4f) plans 
indicating the greater error in the brainstem on the A(4f) plan. Figure 4(c) is included to show 
how the plans react differently to random set-up errors, especially the C(4f) plan which shows a 
Table 3. Robustness values for each parameter set in the site specific ROBUSTNESS 
database in table  2 for plans A(4f) and B(4f). Bold values are those that are out of 
tolerance, and the italic values are those on the upper tolerance limit.
VOI
Mean  
range (%)
Mean  
setup (%)
Veb3%  
range (%)
Veb5%  
range (%)
Veb5%  
setup (%)
Veb10%  
range (%)
A(4f) Brainstem 3.9 9 43.5 15 84 38
B(4f) Brainstem 1.1 8.7 1.1 1.1 85 33.5
A(4f) Chiasm 1.4 6 2 3.9 1.8 0
B(4f) Chiasm 2.4 8.7 23 1.4 4 0
A(4f) CTV 2.1 5.2 16.5–28 3 36.5 7
B(4f) CTV 2.8 5.3 26 8.5 38 10
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decrease in robustness when compared the other four beam arrangements for this type of error. As 
seen in the A(4f) plan there is a hot spot in the centre of the brainstem, whereas in the B(4f) the 
hot spot is shifted more anteriorly due to the direction of the lateral and posterior beams. Despite 
this improvement in robustness in the brainstem to range errors, the B(4f) plan is less robust in 
the chiasm (figure 4(c)) compared to the A(4f), whereas the B(6f) yields the greatest robustness 
to range errors in the chiasm of all the plans. In the case of the optic nerves again the B(4f) plan 
is less robust compared to the A(4f), but this time the A(6f) plan is most robust. These results can 
also be seen in table 3, the chiasm fails a robustness constraint with a Veb3% range error of 23%, 
though this error in dose has fallen to 1.4% at Veb5%, matching that achieved by the A(4f) plan.
Table 4 has been included to show the results for four of the plans for other OARS, though 
constraints for these volumes have not been established currently.
4. Discussion
3D IMPT offers the ability to deliver highly conformal radiotherapy to the patient, reducing 
integral normal tissue dose (Chang et al 2006) and providing greater OAR sparing through the 
use of multiple inhomogeneous fields. However, without certainty in our ability to deliver these 
highly complex and conformal plans at each fraction caution must be heeded when choosing 
beam arrangements and positioning steep dose gradients near OARs (Lomax 2008a, Albertini 
et al 2010, McGowan et al 2013). As mentioned, any uncertainty might lead to severe target 
underdosage or OAR overdosage. Several authors are proposing to include the plan robust-
ness as an extra parameter directly during the optimization process (Unkelbach et al 2007, 
Pflugfelder 2008, Fredriksson et al 2011, Chen et al 2012, Liu et al 2012). Unfortunately 
when introducing the robustness parameter into the optimization algorithm, the nominal plan 
conformality is often compromised (Unkelbach et al 2007, Fredriksson et al 2011). We believe 
Table 4. Robustness values for each parameter used the site specific ROBUSTNESS 
database in table 2 for the other OARs analysed for plans A(4f), B(4f), A(6f) and B(6f). 
Tolerances have not been set for these OARs currently and are simply used to further 
compare plans.
VOI beams Mean range Mean setup
Veb3% 
range (%)
Veb5% 
range (%)
Veb5% 
setup (%)
Veb10% 
setup (%)
Cochlea
B(4f) 4 6.8 64.2 32.1 68.2 5.5
A(4f) 3.8 4 84.4 24.8 20.2 1.8
B(6f) 3.7 5.8 57.8 22.9 75.2 1.8
A(6f) 3.9 3.4 75.2 24.8 10.1 1.8
Left optic Nerve
B(4f) 3.8 5.8 36 19 47 14.2
A(4f) 3.8 5.8 36 19 47 14.2
B(6f) 4.4 4.9 23.7 8.3 38.3 14.2
A(6f) 2.1 5.8 9.5 1.2 47.5 12.5
Left temporal lobe
B(4f) 4.2 43 15.3 10.6 19.1 4.8
A(4f) 3 3.8 11.4 6.8 12.9 2
B(6f) 3.2 3.8 11.7 7.2 15.3 2.6
A(6f) 3.1 4 12.5 7.8 16.5 2.1
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Figure 3. Volume histogram of (a) systematic range errors for an underdose scenario 
in the CTV and (b) random set-up errors for an underdose scenario in the CTV for 
five plans of different beam orientations, for five plans of different beam orientations. 
(c) Shows the dose distribution (top) in the CTV (green outline) for the A(4f) (top left) 
and B(4f) (top right) plans and ebDD of systematic range errors for the worst-case 
underdose scenario in the CTV (bottom) for the A(4f) (bottom left) and B(4f)(bottom 
right) plans.
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Figure 4. Volume histogram of (a) the systematic range errors, (b) the random set-
up errors for an overdose scenario in the brainstem and (c) the random set-up errors 
for overdose scenario in the chiasm, for five plans of different beam orientations. 
(d) shows the dose distributions from the A(4f) (top left) and B(4f) (top right) plans and 
the corresponding ebDD from B(4f) (bottom left) and A(4f) (bottom right) treatment 
plans showing the brainstem in green and the target in yellow.
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that the use of a robust plan is probably the correct way to deal with the problem of uncer-
tainties for the IMPT plan. However, we also think that it is extremely important to define a 
threshold between robustness and plan conformality. In particular it is important to establish 
an adequate tolerance level of robustness for each volume. This can be used both as an input 
parameter during the robust optimization process, and also as control parameter during the 
plan evaluation phase. In this way the DATABASE is a compatible method for analysing plan 
robustness alongside robust optimization, as a method of providing feedback and of providing 
a threshold between plan robustness and plan conformality.
Additionally, in this paper it has been demonstrated how retrospective analysis of the 
robustness of clinical plans at PSI has furthered an understanding of how random set-up and 
systematic range errors effect the final dose distribution. It was seen that random set-up errors 
resulted in a greater difference in the resulting dose distribution than that from systematic 
range errors. However, this is valid when only one fraction is considered. When considering 
the full treatment, the random nature of set-up errors act to ‘blur’ the final dose distribution, 
therefore, the risk of reduced plan quality associated with these errors is less. In contrast range 
errors pose a greater concern due to their systematic origin, meaning they are present over the 
entire treatment leading to a cumulative ‘shift’ of the dose distribution, thereby reducing plan 
quality.
Through retrospectively analysing the robustness of each VOI a site-specific Robustness 
DATABASE was established (table 2). For the time being there are no established action lev-
els, or methods for establishing action levels, for evaluating plan robustness. With the aware-
ness that the clinical results achieved for patients treated intra-cranially for chordoma and 
chondrosarcomas at our institute were good (5 years of local control of 81% for chordomas 
and of 94% for chondrosarcomas patients, with only limited toxicities (Ares et al 2009)), we 
assumed that most of the plans clinically delivered in our centre were acceptable also in terms 
of robustness. Consequently, the proposed DATABASE can be used in the future to easily 
identify outliers. For these patients greater plan individualization may be required to improve 
the robustness to uncertainties. Although the DATABASE is specific to PSI, the idea behind 
can be used as an example for other centres to define their own robustness tolerance levels, 
based on experience and treatment technique. Hopefully, as more centres begin to introduce 
robustness evaluation into the clinical workflow we will in the future be able to define an 
adequate level of robustness for each volume of interest. In this way, robustness constraints 
that are accepted worldwide may be established in the same way as dose volume constraints 
to OAR and prescribed dose to target volumes are generally widely accepted and applied in 
the different protocols.
5. Conclusions
The error-bar-dose-distribution (ebDD) has been used to effectively analysis plan robustness 
to both systematic range and random set-up errors for 16 skull base IMPT plans previously 
treated at PSI. A site specific Robustness DATABASE was created as a simple solution to 
include robustness in plan analysis, as well as to aid planners produce plans to meet both dosi-
metric and robustness criteria by establishing site specific robustness thresholds. Using these 
methods further work can be carried out to fully explore how start conditions, and the optimi-
zation itself, affect both the plan robustness and conformality. This will further our ability to 
determine where a trade-off can be made between these two parameters to ensure the patient 
receives as optimal treatment as possible.
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